2024-11-29 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**1. Performance Comparison & Summary:**

Merck & Co Inc (MRK), a leading pharmaceutical company, has shown a cumulative return of 74.83% over a specified period.  Compared to the S&P 500 (VOO) with a cumulative return of 128.86%, MRK underperformed by 54.0 percentage points.  This places its relative underperformance at the 12.1 percentile based on historical data's minimum and maximum range.  The provided alpha and beta analysis shows variable performance relative to the market (S&P 500) across different time periods.


**2. Recent Price Movement:**

* **Closing Price:** $103.12 (Last Market: $103.08)
* **5-Day Moving Average:** $100.99
* **20-Day Moving Average:** $100.03
* **60-Day Moving Average:** $107.81

The stock price is currently above its 5-day and 20-day moving averages, suggesting short-term upward momentum. However, it's below its 60-day moving average, indicating a potential longer-term downtrend.  The price is relatively close to the last market price indicating no significant immediate price swings.


**3. Technical Indicators & Expected Return:**

* **RSI:** 55.88 (Neither overbought nor oversold, suggesting neutral momentum)
* **PPO:** 0.84 (Positive, indicating bullish momentum)
* **20-Day Relative Divergence:** -8.4% (Short-term downward trend)
* **Expected Return:** 0.0% (This represents the expected return relative to the S&P 500 over a long-term (2+ years) holding period with regular investment, indicating no expected outperformance).


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility.  Revenue has generally shown slight increases quarter-over-quarter, with some fluctuations. EPS also fluctuates, but the most recent quarter shows a decrease compared to the previous one.  Without access to expected earnings, a definitive assessment of beats or misses isn't possible.  Note that there is a duplicate entry for 2024-11-06.

**Analysis:**

* **Revenue Growth:**  Generally positive, but not consistently strong growth.
* **EPS Trends:**  Inconsistent, showing both increases and decreases across the provided quarters.
* **Significant Changes:** A noticeable decline in EPS from $2.15 (2024-08-05) to $1.25 (2024-11-06).


**5. Financial Information Analysis:**

**Revenue and Profitability:** Revenue is relatively stable, showing moderate growth. Profit margins are high but show slight quarter-over-quarter decrease in recent quarters.

**Capital and Profitability:** Equity has generally shown a growth trend, while ROE is quite volatile, experiencing a negative value in Q4 2023.

**Overall Financial Health:** The financial data suggests a profitable company with solid revenue, although profitability and return on equity fluctuate.


**6. News and Recent Issues:**

No recent (within the last two days) earnings news is provided.  Information on market outlook, analyst opinions, and performance highlights are missing.


**7. Overall Analysis:**

MRK's performance has lagged the S&P 500 over the period considered.  While recent price action suggests some short-term positive momentum, the longer-term trend appears slightly bearish. The financial statements show a generally healthy company with fluctuating profitability.  More information is needed regarding recent news, analyst opinions and expected earnings to provide a more comprehensive assessment.  The 0% expected return relative to the S&P 500 over the long term suggests potential for similar performance to the market benchmark. The company's financial stability seems solid but requires further deep dive analysis.


**8.  Disclaimer:** This report is based solely on the provided data and does not constitute financial advice.  Investing in the stock market involves risk, and past performance is not indicative of future results.  Conduct thorough research and consult with a financial advisor before making any investment decisions.
